8 completed, 2 active not recruiting, 1 terminated, 1 withdrawn. 9 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Active not recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 3 |
Follow Palatin Technologies, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity bremelanotide, tirzepatide - Obesity | Phase 2 | Active not recruiting | Palatin Technologies, Inc | 108 | 2024-08-05 | 2025-03-06 |
| A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease Bremelanotide, RAAS inhibition therapy - Kidney Disease | Phase 2 | Completed | Palatin Technologies, Inc | 16 | 2022-12-26 | 2024-10-17 |
| Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) PL8177 Placebo, PL8177 - Ulcerative Colitis, Ulcerative Colitis Acute | Phase 2 | Active not recruiting | Palatin Technologies, Inc | 16 | 2022-09-15 | 2025-03-05 |
| A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye Vehicle Ophthalmic Solution, PL9643 Ophthalmic Solution - Dry Eye, Dry Eye Syndromes | Phase 3 | Completed | Palatin Technologies, Inc | 575 | 2021-12-30 | 2024-10-17 |
| Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects PL-3994 Aqueous Intravenous Solution Dose Ascention, PL-3994 Aqueous Intravenous Solution Single Dose - Heart Failure With Preserved Ejection Fraction | Phase 2 | Terminated | Palatin Technologies, Inc | 15 | 2020-11-12 | 2025-12-15 |
| Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye PL9643 Ophthalmic Solution, Placebo Ophthalmic Solution - Dry Eye Disease | Phase 2 | Completed | ORA, Inc. | 160 | 2020-02-14 | 2020-11-13 |
| 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder Bremelanotide, Placebo - Hypoactive Sexual Desire Disorder | Phase 3 | Completed | Palatin Technologies, Inc | 714 | 2015-01-01 | 2021-01-28 |
| 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder Bremelanotide, Placebo - Hypoactive Sexual Desire Disorder | Phase 3 | Completed | Palatin Technologies, Inc | 723 | 2014-12-01 | 2021-04-09 |
| Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder bremelanotide - Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder | Phase 2 | Completed | Palatin Technologies, Inc | 612 | 2011-06-01 | 2014-12-18 |
| Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension PL3994, Placebo - Hypertension | Phase 2 | Completed | Palatin Technologies, Inc | 21 | 2008-04-01 | 2013-07-19 |
| Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD) Bremelanotide - Sexual Arousal Disorder | Phase 2 | Completed | Palatin Technologies, Inc | 2006-02-01 | 2011-02-23 | |
| Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma PL-3994 - Asthma | Phase 2 | Withdrawn | Palatin Technologies, Inc | 2014-12-16 |
Sexual Dysfunctions, Psychological (4) · Dry Eye Syndromes (2) · Asthma (1) · Colitis, Ulcerative (1) · Conjunctival Diseases (1) · Corneal Diseases (1) · Eye Diseases (1) · Heart Failure (1) · Hypertension (1) · Kidney Diseases (1) · Obesity (1) · Ulcer (1)
bremelanotide (6) · PL-3994 (3) · Angiotensin Receptor Antagonists (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Tirzepatide (1)
United States (11) · Canada (3)
Robert Jordan (5) · Brian Dodge (1) · James Tumlin, MD (1) · Jeffrey Edelson, MD, FRCPC (1) · Robert Jordan, VP Clinical Operations (1) · Sangiv J. Shah, MD (1) · Steven Fischkoff, MD (1)
PMID 10782451, PMID 28189361, PMID 31599840, PMID 31599847, PMID 33033885, PMID 33538638, PMID 35147466, PMID 36809187, PMID 27181790, PMID 34559353, PMID 37677000